I think that if they partner Ponatinib with some other company OTHER than Merck, it pretty much takes a buyout off the table IMO. Any time you have a company with multiple partners, in multiple drugs, it just begins to really complicate matters in M&A. Not to say it hasn't been done, it's just less likely.